2018 Q3 Form 10-Q Financial Statement
#000156459018028639 Filed on November 08, 2018
Income Statement
Concept | 2018 Q3 | 2017 Q4 | 2017 Q3 |
---|---|---|---|
Revenue | $18.01M | $10.00K | $10.00K |
YoY Change | 180000.0% | 0.0% | -9.09% |
Cost Of Revenue | |||
YoY Change | |||
Gross Profit | |||
YoY Change | |||
Gross Profit Margin | |||
Selling, General & Admin | $4.320M | $2.400M | $2.180M |
YoY Change | 98.17% | 77.78% | 127.08% |
% of Gross Profit | |||
Research & Development | $12.26M | $8.290M | $7.560M |
YoY Change | 62.17% | 25.04% | -0.4% |
% of Gross Profit | |||
Depreciation & Amortization | $200.0K | $90.00K | $70.00K |
YoY Change | 185.71% | 28.57% | 0.0% |
% of Gross Profit | |||
Operating Expenses | $16.58M | $10.70M | $9.747M |
YoY Change | 70.12% | 33.95% | 14.11% |
Operating Profit | $1.427M | -$9.737M | |
YoY Change | -114.66% | 14.14% | |
Interest Expense | -$300.0K | -$150.0K | -$220.0K |
YoY Change | 36.36% | -67.39% | -53.19% |
% of Operating Profit | -21.02% | ||
Other Income/Expense, Net | -$301.0K | -$216.0K | |
YoY Change | 39.35% | -53.94% | |
Pretax Income | $1.126M | -$10.84M | -$9.953M |
YoY Change | -111.31% | 28.59% | 10.59% |
Income Tax | $1.509M | ||
% Of Pretax Income | 134.01% | ||
Net Earnings | -$383.0K | -$10.84M | -$9.953M |
YoY Change | -96.15% | 28.55% | 10.59% |
Net Earnings / Revenue | -2.13% | -108370.0% | -99530.0% |
Basic Earnings Per Share | |||
Diluted Earnings Per Share | -$285.7K | -$8.150M | -$7.538M |
COMMON SHARES | |||
Basic Shares Outstanding | |||
Diluted Shares Outstanding |
Balance Sheet
Concept | 2018 Q3 | 2017 Q4 | 2017 Q3 |
---|---|---|---|
SHORT-TERM ASSETS | |||
Cash & Short-Term Investments | $79.80M | $88.73M | $99.57M |
YoY Change | -19.86% | 183.97% | 171.32% |
Cash & Equivalents | $23.48M | $35.93M | $74.84M |
Short-Term Investments | $56.40M | $52.79M | $24.73M |
Other Short-Term Assets | $5.200M | $1.900M | $1.200M |
YoY Change | 333.33% | 58.33% | -29.41% |
Inventory | |||
Prepaid Expenses | |||
Receivables | |||
Other Receivables | |||
Total Short-Term Assets | $85.10M | $90.63M | $100.8M |
YoY Change | -15.58% | 179.19% | 163.19% |
LONG-TERM ASSETS | |||
Property, Plant & Equipment | $4.000M | $1.217M | $1.000M |
YoY Change | 300.0% | 63.8% | 25.0% |
Goodwill | |||
YoY Change | |||
Intangibles | |||
YoY Change | |||
Long-Term Investments | |||
YoY Change | |||
Other Assets | $1.237M | $227.0K | $300.0K |
YoY Change | 312.33% | -89.43% | -84.21% |
Total Long-Term Assets | $5.253M | $1.444M | $1.400M |
YoY Change | 275.21% | -50.03% | -48.15% |
TOTAL ASSETS | |||
Total Short-Term Assets | $85.10M | $90.63M | $100.8M |
Total Long-Term Assets | $5.253M | $1.444M | $1.400M |
Total Assets | $90.35M | $92.07M | $102.2M |
YoY Change | -11.59% | 160.45% | 149.27% |
SHORT-TERM LIABILITIES | |||
YoY Change | |||
Accounts Payable | $4.555M | $1.951M | $1.200M |
YoY Change | 279.58% | 17.11% | -36.84% |
Accrued Expenses | $10.00M | $8.120M | $8.300M |
YoY Change | 20.52% | 49.35% | 59.62% |
Deferred Revenue | $36.00K | ||
YoY Change | |||
Short-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Long-Term Debt Due | $7.200M | $7.200M | |
YoY Change | 0.0% | 20.0% | |
Total Short-Term Liabilities | $14.60M | $17.33M | $16.70M |
YoY Change | -12.57% | 20.5% | 25.56% |
LONG-TERM LIABILITIES | |||
Long-Term Debt | $26.10M | $3.625M | $5.300M |
YoY Change | 392.45% | -64.6% | -57.94% |
Other Long-Term Liabilities | $2.000M | $0.00 | $0.00 |
YoY Change | -100.0% | -100.0% | |
Total Long-Term Liabilities | $28.10M | $3.625M | $5.300M |
YoY Change | 430.19% | -64.6% | -58.27% |
TOTAL LIABILITIES | |||
Total Short-Term Liabilities | $14.60M | $17.33M | $16.70M |
Total Long-Term Liabilities | $28.10M | $3.625M | $5.300M |
Total Liabilities | $42.70M | $20.99M | $22.06M |
YoY Change | 93.61% | -25.97% | -15.17% |
SHAREHOLDERS EQUITY | |||
Retained Earnings | -$166.9M | ||
YoY Change | 30.41% | ||
Common Stock | $238.0M | ||
YoY Change | 6543.73% | ||
Preferred Stock | |||
YoY Change | |||
Treasury Stock (at cost) | |||
YoY Change | |||
Treasury Stock Shares | |||
Shareholders Equity | $47.67M | $71.08M | $80.12M |
YoY Change | |||
Total Liabilities & Shareholders Equity | $90.40M | $92.07M | $102.2M |
YoY Change | -11.52% | 160.45% | 149.2% |
Cashflow Statement
Concept | 2018 Q3 | 2017 Q4 | 2017 Q3 |
---|---|---|---|
OPERATING ACTIVITIES | |||
Net Income | -$383.0K | -$10.84M | -$9.953M |
YoY Change | -96.15% | 28.55% | 10.59% |
Depreciation, Depletion And Amortization | $200.0K | $90.00K | $70.00K |
YoY Change | 185.71% | 28.57% | 0.0% |
Cash From Operating Activities | $940.0K | -$9.170M | -$7.040M |
YoY Change | -113.35% | 18.32% | -11.34% |
INVESTING ACTIVITIES | |||
Capital Expenditures | -$620.0K | -$320.0K | -$230.0K |
YoY Change | 169.57% | 3100.0% | -36.11% |
Acquisitions | |||
YoY Change | |||
Other Investing Activities | -$1.460M | -$28.08M | $7.810M |
YoY Change | -118.69% | -509.93% | 15.19% |
Cash From Investing Activities | -$2.080M | -$28.40M | $7.570M |
YoY Change | -127.48% | -515.2% | 17.73% |
FINANCING ACTIVITIES | |||
Cash Dividend Paid | |||
YoY Change | |||
Common Stock Issuance & Retirement, Net | |||
YoY Change | |||
Debt Paid & Issued, Net | |||
YoY Change | |||
Cash From Financing Activities | 0.000 | -1.340M | -1.800M |
YoY Change | -100.0% | -157.51% | -662.5% |
NET CHANGE | |||
Cash From Operating Activities | 940.0K | -9.170M | -7.040M |
Cash From Investing Activities | -2.080M | -28.40M | 7.570M |
Cash From Financing Activities | 0.000 | -1.340M | -1.800M |
Net Change In Cash | -1.140M | -38.91M | -1.270M |
YoY Change | -10.24% | -2840.14% | 6.72% |
FREE CASH FLOW | |||
Cash From Operating Activities | $940.0K | -$9.170M | -$7.040M |
Capital Expenditures | -$620.0K | -$320.0K | -$230.0K |
Free Cash Flow | $1.560M | -$8.850M | -$6.810M |
YoY Change | -122.91% | 14.34% | -10.16% |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
CY2017Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
20000 | |
CY2017Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
238025000 | |
CY2017Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-166929000 | |
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
15021000 | ||
us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
337000 | ||
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-4946000 | ||
us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
2646720 | ||
CY2018Q3 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
1237000 | |
CY2018Q3 | us-gaap |
Assets
Assets
|
90353000 | |
CY2018Q3 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
4555000 | |
CY2018Q3 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
10003000 | |
CY2017Q4 | us-gaap |
Notes Payable Current
NotesPayableCurrent
|
7200000 | |
CY2018Q3 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
36000 | |
CY2017Q4 | toca |
Deferred Grant Funding
DeferredGrantFunding
|
23000 | |
CY2018Q3 | us-gaap |
Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
|
2027000 | |
CY2017Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
CY2017Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-34000 | |
CY2017Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
90603000 | ||
CY2017Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
74842000 | |
CY2017Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
CY2017Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
CY2017Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
CY2018Q3 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
1126000 | |
CY2017Q3 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-9953000 | |
CY2018Q3 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
1509000 | |
us-gaap |
Paid In Kind Interest
PaidInKindInterest
|
1016000 | ||
us-gaap |
Paid In Kind Interest
PaidInKindInterest
|
441000 | ||
toca |
Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
|
784000 | ||
toca |
Increase Decrease In Deferred Grant Funding
IncreaseDecreaseInDeferredGrantFunding
|
-11000 | ||
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-22526000 | ||
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-21961000 | ||
us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
32651000 | ||
us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
31644000 | ||
us-gaap |
Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
|
20000 | ||
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
690000 | ||
toca |
Proceeds From Issuance Of Notes Payable Net Of Issuance Costs
ProceedsFromIssuanceOfNotesPayableNetOfIssuanceCosts
|
26325000 | ||
us-gaap |
Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
|
8631000 | ||
us-gaap |
Repayments Of Notes Payable
RepaymentsOfNotesPayable
|
3000000 | ||
us-gaap |
Repayments Of Notes Payable
RepaymentsOfNotesPayable
|
5400000 | ||
us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
327000 | ||
us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
47000 | ||
toca |
Proceeds From Offering Of Common Net Of Stock Issuance Costs
ProceedsFromOfferingOfCommonNetOfStockIssuanceCosts
|
88618000 | ||
us-gaap |
Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
|
7338000 | ||
us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-12451000 | ||
us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
69332000 | ||
CY2016Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
5510000 | |
toca |
Allowance For Tenant Improvements Included In Deferred Rent
AllowanceForTenantImprovementsIncludedInDeferredRent
|
1243000 | ||
toca |
Fair Value Of Common Stock Warrants Issued In Connection With Notes Payable
FairValueOfCommonStockWarrantsIssuedInConnectionWithNotesPayable
|
479000 | ||
toca |
Convertible Preferred Stock Converted Into Shares Of Common Stock
ConvertiblePreferredStockConvertedIntoSharesOfCommonStock
|
131410000 | ||
toca |
Convertible Promissory Notes Principal And Accrued Interest Converted Into Shares Of Common Stock
ConvertiblePromissoryNotesPrincipalAndAccruedInterestConvertedIntoSharesOfCommonStock
|
11092000 | ||
toca |
Preferred Stock Warrants Liabilities Converted Into Warrants To Purchase Share Of Common Stock
PreferredStockWarrantsLiabilitiesConvertedIntoWarrantsToPurchaseShareOfCommonStock
|
89000 | ||
CY2018Q3 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
193000 | |
toca |
Deferred Equity Issuance Cost Payment Reclassified Of Equity Effective Intial Public Offering
DeferredEquityIssuanceCostPaymentReclassifiedOfEquityEffectiveIntialPublicOffering
|
1574000 | ||
toca |
Deferred Debt And Equity Issuance Costs Incurred But Not Yet Paid
DeferredDebtAndEquityIssuanceCostsIncurredButNotYetPaid
|
96000 | ||
us-gaap |
Use Of Estimates
UseOfEstimates
|
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The Company’s financial statements are prepared in accordance with GAAP, which requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities in the financial statements and accompanying notes. Significant estimates in the Company’s financial statements relate to clinical trial accruals, the valuation of equity awards, and the development period used for license revenue recognition. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results may differ from these estimates under different assumptions or conditions.</p></div> | ||
CY2017Q4 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
77000 | |
CY2018Q3 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
230000 | |
us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | ||
us-gaap |
Initial Offering Period
InitialOfferingPeriod
|
April 19, 2017 | ||
CY2017Q2 | us-gaap |
Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
|
86900000 | |
CY2018Q3 | toca |
Working Capital
WorkingCapital
|
70500000 | |
CY2018Q3 | us-gaap |
Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
|
79800000 | |
CY2018Q3 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
3704740 | |
CY2017Q3 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
2646720 | |
us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
3704740 | ||
CY2018Q3 | us-gaap |
Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
|
0 | |
CY2017Q3 | us-gaap |
Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
|
0 | |
CY2018Q3 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
1000 | |
CY2018Q3 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
24000 | |
CY2017Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
31000 | |
CY2017Q4 | us-gaap |
Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
|
52792000 | |
us-gaap |
Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net
OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet
|
0 | ||
CY2018Q3 | toca |
Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
|
4293000 | |
CY2017Q4 | toca |
Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
|
2809000 | |
CY2018Q3 | toca |
Accrued Contract Manufacturing Services Current
AccruedContractManufacturingServicesCurrent
|
1371000 | |
CY2017Q4 | toca |
Accrued Contract Manufacturing Services Current
AccruedContractManufacturingServicesCurrent
|
1536000 | |
CY2018Q3 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
2665000 | |
CY2017Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
2489000 | |
CY2017Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
276000 | |
CY2018Q3 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
1251000 | |
CY2017Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
933000 | |
CY2018Q3 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
4368468 | |
CY2018Q3 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1927000 | |
CY2017Q3 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1491000 | |
us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
5120000 | ||
us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
3076000 |